Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue
Cancer Cell · 2024
DOI: 10.1016/j.ccell.2024.05.020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2024. Verfasst von Naiara Perurena und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: NCI.
Abstract (Originalsprache)
The development of mutant-selective KRAS inhibitors represents a major therapeutic advance; however, patients can develop resistance through feedback mechanisms and genetic alterations in the RAS pathway. Three publications in Nature and Cancer Discovery describe a promising RAS(ON) multi-selective inhibitor that simultaneously targets oncogenic RAS and multiple potential resistance mechanisms while sparing normal tissue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
- Division of Genetics, Brigham and Women's Hospital, Boston, MA 02115, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA.…
Förderung
- NCI
Zitieren
APA
Perurena, N., & Cichowski, K. (2024). Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue. Cancer Cell. https://doi.org/10.1016/j.ccell.2024.05.020
Vancouver
Perurena N, Cichowski K. Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue. Cancer Cell. 2024. doi:10.1016/j.ccell.2024.05.020
BibTeX
@article{Perurena2024,
author = {Perurena, Naiara and Cichowski, Karen},
title = {Finding the sweet spot: Targeting RAS in tumors while sparing normal tissue},
journal = {Cancer Cell},
year = {2024},
doi = {10.1016/j.ccell.2024.05.020}
}
EUVIMED